Procyrion, located in Houston, Texas was one of the laureates of 2015 Innovation Prize organized by Universal Biotech, subsidiary of Universal Medica Group. The start-up is developing Aortix™ a first-in-class circulatory assist device for ambulatory treatment of chronic heart failure. Heart failure affects over 6M people just in the US alone and around 600,000 new cases are diagnosed every year. The healthcare costs of treating

2016 was an outstanding year for our competition, we received applications from 38 countries, a new record! With a growing international attractiveness, the Innovation Prize became an essential event for worldwide healthcare entrepreneurs. This year, 259 project holders applied to the Innovation Prize In the opinion of the organizers:  « the participant’s profile is evolving each year: some projects aim at dealing with unmet medical needs, other

Held in San Francisco from June 6th to 9th, the BIO2016 is one of the largest global annual gathering of the Biotech world. At this meeting, not only stakeholders from either ends of the spectrum are attendees but also decision makers and key influencers who altogether form the support sphere for the life sciences industry. Universal Biotech, a subsidiary of Universal Medica Group has been

Innovation Days is the unique international networking event focused on Life Sciences innovations, held on October 3rd and 4th in Paris, France. For its 7th edition, this event will gather executives from Biotech, Medtech, Pharmaceutical companies together with Investors and Service Providers to maximize partnership opportunities. This edition, sponsored by Pierre-Fabre, L’Oréal, Servier, Taylor Wessing, CleveXel Pharma and Cherry for Lifescience will be held on the

Universal Biotech, filiale d’Universal Medica Group, est fière de vous présenter l’interview de Rafi Mardachti, président directeur général de Universal Medica Group et organisateur du Prix de l’Innovation et des Innovation Days, dans la revue Pharmaceutiques de Janvier 2016. Découvrez comment la stimulation de synergies entre les acteurs économiques des sciences de la vie permet la valorisation de projets biotech, medtech et digitaux à l’échelle